美国化学会。第240次全国会议。预防和对抗疾病的化学:第2部分。

Idrugs Pub Date : 2010-10-01
Alexandra Kibble
{"title":"美国化学会。第240次全国会议。预防和对抗疾病的化学:第2部分。","authors":"Alexandra Kibble","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"673-6"},"PeriodicalIF":0.0000,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.\",\"authors\":\"Alexandra Kibble\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).</p>\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 10\",\"pages\":\"673-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在波士顿举行的第240届美国化学学会全国会议的主题涵盖了新的治疗研究。本次会议报告重点介绍了用于治疗阿尔茨海默病的(S)-腺苷型同型半胱氨酸(AHCY)抑制剂,用于治疗疼痛的2,4-二苯基- 1h -咪唑类似物作为大麻素CB2激动剂,作为癌症治疗靶点的检查点激酶1 (Chk1)和Aurora激酶B,作为VEGFR2抑制剂的吡啶甲基硫衍生物,以及用于治疗骨髓增生性疾病的Janus激酶2 (JAK2)。讨论的研究药物包括L-002259713(默克)、AZD-1480(阿斯利康)、CYT-387 (YM Biosciences)和ruxolitinib (Incyte)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.

The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Idrugs
Idrugs 医学-药学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Neurodegenerative diseases. Edotecarin. Tesaglitazar. Anti-inflammatory drugs Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1